Replimune Group, Inc. (REPL)
14.69
-0.08
(-0.54%)
USD |
NASDAQ |
Aug 24, 16:00
14.69
0.00 (0.00%)
After-Hours: 20:00
Replimune Group Total Liabilities (Quarterly) : 146.80M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 146.80M |
| March 31, 2026 | 166.23M |
| December 31, 2025 | 123.05M |
| September 30, 2025 | 126.11M |
| June 30, 2025 | 132.79M |
| March 31, 2025 | 135.48M |
| December 31, 2024 | 121.25M |
| September 30, 2024 | 116.74M |
| June 30, 2024 | 108.51M |
| March 31, 2024 | 113.21M |
| December 31, 2023 | 111.39M |
| September 30, 2023 | 97.23M |
| June 30, 2023 | 89.86M |
| March 31, 2023 | 91.30M |
| December 31, 2022 | 83.20M |
| September 30, 2022 | 52.02M |
| June 30, 2022 | 49.16M |
| March 31, 2022 | 49.96M |
| December 31, 2021 | 47.77M |
| Date | Value |
|---|---|
| September 30, 2021 | 46.05M |
| June 30, 2021 | 44.70M |
| March 31, 2021 | 44.37M |
| December 31, 2020 | 43.00M |
| September 30, 2020 | 52.85M |
| June 30, 2020 | 51.77M |
| March 31, 2020 | 50.38M |
| December 31, 2019 | 52.86M |
| September 30, 2019 | 30.80M |
| June 30, 2019 | 13.39M |
| March 31, 2019 | 16.47M |
| December 31, 2018 | 8.948M |
| September 30, 2018 | 3.78M |
| June 30, 2018 | 11.63M |
| March 31, 2018 | 6.858M |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | 2.725M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Moderna, Inc. | 4.20B |
| Kalaris Therapeutics, Inc. | 41.87M |
| Arrowhead Pharmaceuticals, Inc. | 1.646B |
| Oncolytics Biotech, Inc. | 13.84M |
| Sangamo Therapeutics, Inc. | 78.92M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 252.45M |
| Shareholders Equity (Quarterly) | 105.64M |
| Debt to Equity Ratio | 1.060 |
| Current Ratio | 5.228 |
| Net Debt Paydown Yield | -0.77% |